<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Obstet Gynecol</journal-id><journal-id journal-id-type="publisher-id">IDOG</journal-id><journal-title>Infectious Diseases in Obstetrics and Gynecology</journal-title><issn pub-type="ppub">1064-7449</issn><issn pub-type="epub">1098-0997</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19190779</article-id><article-id pub-id-type="pmc">2631650</article-id><article-id pub-id-type="doi">10.1155/2008/840948</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Infection with Hepatitis C Virus among HIV-Infected Pregnant Women in Thailand</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jamieson</surname><given-names>Denise J.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Skunodom</surname><given-names>Natapakwa</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chaowanachan</surname><given-names>Thanyanan</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roongpisuthipong</surname><given-names>Anuvat</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bower</surname><given-names>William A.</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chotpitayasunondh</surname><given-names>Tawee</given-names></name><xref ref-type="aff" rid="I5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhanich Supapol</surname><given-names>Wendy</given-names></name><xref ref-type="aff" rid="I6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuhnert</surname><given-names>Wendi L.</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Siriwasin</surname><given-names>Wimol</given-names></name><xref ref-type="aff" rid="I7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wiener</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chearskul</surname><given-names>Sanay</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>McConnell</surname><given-names>Michelle S.</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shaffer</surname><given-names>Nathan</given-names></name><xref ref-type="aff" rid="I8"><sup>8</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341-3717, USA</aff><aff id="I2"><sup>2</sup>Thailand MOPH-U.S. CDC Collaboration, CDC, Nonthaburi 11000, Thailand</aff><aff id="I3"><sup>3</sup>Faculty of Medicine Siriraj Hospital, Mahidol Univeristy, Siriraj, Bangkoknoi, Bangkok 10700, Thailand</aff><aff id="I4"><sup>4</sup>Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA</aff><aff id="I5"><sup>5</sup>Queen Sirikit National Institute of Child Health, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand</aff><aff id="I6"><sup>6</sup>Department of Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada ON M5S 1A8</aff><aff id="I7"><sup>7</sup>Department of Medical Services, Rajavithi Hospital, Ministry of Public Health (MOPH), Bangkok 10400, Thailand</aff><aff id="I8"><sup>8</sup>Global AIDS Program, Centers for Disease Control and Prevention, Atlanta,  GA 30333, USA</aff><author-notes><corresp id="cor1">*Denise J. Jamieson: <email>djj0@cdc.gov</email></corresp><fn fn-type="other"><p>Recommended by Daniel Landers</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>27</day><month>1</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>840948</elocation-id><history><date date-type="received"><day>5</day><month>3</month><year>2008</year></date><date date-type="rev-recd"><day>28</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Denise J. Jamieson et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Objective</italic>. The purpose of this study was to describe the epidemiology of coinfection with hepatitis C virus (HCV) and HIV among a cohort of pregnant Thai women. <italic>Methods</italic>. Samples from 1771 pregnant women enrolled in three vertical transmission of HIV studies in Bangkok, Thailand, were tested for HCV.   <italic>Results</italic>. Among HIV-infected pregnant women, HCV seroprevelance was 3.8% and the active HCV infection rate was 3.0%. Among HIV-uninfected pregnant women, 0.3% were HCV-infected.  Intravenous drug use by the woman was the factor most strongly associated with HCV seropositivity. Among 48 infants tested for HCV who were born to HIV/HCV coinfected women, two infants were HCV infected for an HCV transmission rate of 4.2% (95% 0.51&#x02013;14.25%).  <italic>Conclusions</italic>. HCV seroprevalence and perinatal transmission rates were low among this Thai cohort of HIV-infected pregnant women.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Worldwide, the hepatitisC virus (HCV)  seroprevalence rate among pregnant women is  approximately 1% [<xref ref-type="bibr" rid="B1">1</xref>].  This is similar to the 1.6% prevalence of HCVantibody in the general population in the United States  [<xref ref-type="bibr" rid="B2">2</xref>].  Among HIV-infected pregnant women, muchhigher prevalences of HCV positivity have been reported, ranging from as highas 30 to 50% in some settings [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>], particularly in populations with highrates of injection drug use.</p><p>Although theperinatal transmission rate of HCV is estimated to be less than 5% amongHIV-uninfected women, it is generally higher in HIV-infected women [<xref ref-type="bibr" rid="B1">1</xref>].  Not all studies, however, have foundincreased HCV transmission rates among HIV-infected women [<xref ref-type="bibr" rid="B5">5</xref>] and a wide rangeof estimates of the risk of vertical transmission of HCV among coinfected womenhas been reported with wide geographic variation [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>].</p><p>The purpose of this study was todescribe the epidemiology of coinfection with hepatitis C virus and HIV among acohort of pregnant Thai women.</p></sec><sec sec-type="section" id="sec2"><title>2. MATERIALS AND METHODS</title><p>The current studypopulation includes 1771 women previously enrolled in three verticaltransmission studies in Bangkok, Thailand  [<xref ref-type="bibr" rid="B8">8</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>] who hadspecimens available for HCV testing. From the first study (peri-1), 342 HIV-uninfected women and 293 HIV-infectedwomen are included.  From the second(peri-2) and third studies (peri-3), 391 and 745 HIV-infected women areincluded, respectively.  Women in thesestudies were either enrolled during antenatal care (peri-1 and 2) or  atdelivery (peri-3).  All children born toHIV-infected women were followedfor 4&#x02013;18 months andtheir mothers did not breastfeed.  Nofollow-up information is available for infants born to HIV-uninfected women inperi-1.  Peri-1 was an observational prospectivecohort study without treatment interventions, peri-2 was a randomizedplacebo-controlled clinical trial assessing the efficacy of short-coursezidovudine prophylaxis antenatally and intrapartum, and peri-3 was an observationalstudy of short-course zidovudine and single-dose nevirapine propylaxis.  All three studies were conducted jointly bythe Thailand Ministry of Public Health and the U.S. Centers for Disease Controland Prevention (CDC) at two large Bangkok  hospitals from 1992 to 2004.  The threeperinatal studies (peri-1,2,3) and this current retrospective laboratory studywere all approved by the institutional review boards at the CDC in Atlanta andthe Ethical Review Committees for Research in Human Subjects at the ThailandMinistry of Public Health and Siriraj Hospital in Bangkok.</p><p>In the originalstudies, specimens were collected and tested for HIV, HIV viral load, CD4 countas previously described [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>].  Storedplasma specimens from pregnancy or delivery were screened for antibodies to  HCV(anti-HCV) using enzyme immunoassay (EIA; Abbott Murex version 4.0, Abbott Laboratories, Abbott Park, Ill USA). All positive EIAs were tested with qualitative reverse transcriptasepolymerase chain reaction (RT-PCR; Ampliscreen, Roche Diagnostic Systems, Branchburg, NJ, USA).  If the qualitative RT-PCR was negative, theplasma specimen was retested with recombinant immunoblot assay (RIBA 3.0,Chiron Corporation, Emeryville, Calif, USA).  All women who were EIA positive and eitherqualitative RT-PCR or RIBA positive are considered HCV infected (either currentor past); all other women are considered HCV uninfected.  All specimens with detectable virus weretested with quantitative PCR (COBAS Amplicor HCV Monitor Test, version 2.0,Roche Diagnostic Systems) with a lower limit of detection of &#x0003c;600copies/mL.  All women with detectablevirus are considered to have active HCV infection.  Specimens with detectable HCV were genotypedusing the Trugene HCV 5&#x02032;NC genotyping kit (Bayer HealthCare LLC, Berkeley, Calif, USA) andsequence analysis with the OpenGene DNA sequencing system.  Results were then confirmed using sequence analysis (ABIPRISM 310 Genetic Analyzer, Applied Biosystems, Calif,USA)methods.  In 8 cases where the results fromthe two techniques were discordant, the 715 nt E1-E2 region at position883-1597 nt was directly sequenced.</p><p>Stored plasma frominfants born to women coinfected with HIV and HCV was also tested for HCV.  An HCV-infected infant was defined as aninfant who was anti-HCV positive (i.e., EIA-positive with confirmatory RIBA) at18 months of age or older or who had positive HCV RNA on two occasions.  Several serial samples from infants weretested, depending on availability of samples and testing results, since HCVinfection often cannot be excluded in infants by one-time testing [<xref ref-type="bibr" rid="B11">11</xref>].  However, due to limited availability infantspecimens, 18/48 (37.5%) of infants tested had testing at only one time point.</p><p>Statistical analyseswere performed using SAS software version 9.1 (SAS Institute, Cary, NC, USA).  Odds ratios with 95% confidence intervalswere estimated using unconditional logistic regression, adjusting for the threeperinatal studies. Ninety-five percent confidence intervals for HCVtransmission rates were estimated using exact binomial methods.</p></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><p>There were low rates of intravenous drug use(1.5%) among the 1771 women included in this study (<xref ref-type="table" rid="tab1">Table 1</xref>).  A higher proportion of women reported severalother risk factors for hepatitis C acquisition, including having an injectiondrug-using partner (10.2%) and ever having been a commercial sex worker(7.8%).  HIV-infected women hadmoderately high CD4 counts at delivery (mean 428 cells/mm<sup>3</sup>); themean viral load at delivery was 10 000 copies/mL.</p><p>Among 1429 HIV-infected pregnant women 62 (4.3%)were found to have HCV antibodies by EIA. Of those, 54 had positive confirmatory testing by either RT-PCR(<italic>n</italic> = 43) or by RIBA (<italic>n</italic> = 11).  Thus, 3.8%(54/1429) of HIV-infected pregnant women were found to be coinfected with HCVand  3.0% (43/1429) had evidence ofactive infection.  Among 342HIV-uninfected women, 2 (0.6%) were found to have HCV antibodies by EIA.  Of those, only one of the women had positiveconfirmatory testing by RT-PCR.  Thus, 0.3% (1/342) of HIV-uninfectedpregnant women were found to be infected with HCV.</p><p>Among the 54HCV-seropositive women, 22 did not receive any antiretroviral prophylaxis, 22received 4 weeks of antenatal zidovudine and intrapartum zidovudine, and 10received 4 weeks of antenatal zidovudine and intrapartum zidovudine andnevirapine. Of the 43 HIV-infected women with quantifiable HCV, the serumlevels of HCV RNA were as follows: 12 women with &#x0003c;100 000 copies/mL, 17women with 100 000&#x02013;850 000copies/mL, and 13 women with &#x0003e;850 000 copies/mL.  One woman who was HCV RNA-PCR positive on thequalitative assay had undetectable virus (&#x0003c;600 copies/mL) on thequantitative assay.  The HIV-uninfectedwoman with quantifiable HCV had a serum level of HCV of 62 000 copies/mL.  The HIV-infected women in later cohorts(peri-2 and peri-3) were more likely to be HCV infected (4.1 and 4.4%, resp.)compared with HIV-infected women in the earlier cohort (1.7%) (see <xref ref-type="table" rid="tab1">Table 1</xref>).  Among the 35 HCV-infected women withconfirmed HCV genotyping results, 14 (40%) were genotype 3a, 14 (40%) weregenotype 1a, 4 (11.4%) were genotype 1b, 2 (5.7%) were genotype 6a, and 1 (2.9%)was genotype 4a.</p><p>In unadjustedanalyses, factors associated with pregnant women being HCV infected included moreeducation, intravenous drug use, having a partner with a history of injectiondrug use, ever having been a commercial sex worker, and having received a bloodtransfusion.   These risk factors remained significant whenadjusting for perinatal study (<xref ref-type="table" rid="tab2">Table 2</xref>). In a multivariate model  adjustedfor all covariates in <xref ref-type="table" rid="tab2">Table 2</xref>, only three factors remained significant:  intravenous drug use (adjusted odds ratio70.5; 95% CI 24.8&#x02013;201), having a partner with a history of injection drug use(adjusted odds ratio 3.4; 95% CI 1.5&#x02013;7.4), and having received a bloodtransfusion (adjusted odds ratio 6.7; 95% CI 1.9&#x02013;23.9).  Since HIV-uninfected women were only includedin peri-1, we included only women in peri-1 when estimating the odds of HCVinfection by HIV status.  This study didnot find an association between HIV infection status and HCV infection (adjustedodds ratio 5.9; 95% CI 0.7&#x02013;51.0).</p><p>For peri-1, all 5 infants born to HIV/HCV-infectedwomen had samples tested for HCV RNA at 2, 4, and 6 months and no infants werefound to be HCV infected.  For peri-2,12/16 infants had 6-month samples available which were tested for HCV RNA and 13/16infants had 18-month samples available which were tested for HCVantibodies.  All infants had testing fromat least one time point and 10 infants were tested at more than one time point.  From peri-2, one infant was HCV-RNA positiveat 6 months; additional testing of a 4-month sample from this infant confirmedthat this infant was HCV-RNA positive. In addition, three infants were anti-HCV positive by EIA at 18months.  However, only one of theseinfants had positive confirmatory testing by RIBA.  For peri-3, 15 infants had serial testing atboth 2 and 4 months and 27 infants had testing performed for at least one time point. No infants were found to be HCV infected.</p><p>In summary, among 48 infants tested for HCVwho were born to HIV/HCV coinfected women, two infants were HCV infected for anHCV transmission rate of 4.2% (95%  0.51&#x02013;14.25%).  One of these infants was born to a woman who wasinfected with HCV genotype 3a and had an HCV viral load of 764 323 copies/mLand an HIV viral load of 2092 copies/mL. The mother of this infant received zidovudine for 4 weeks antenatally andduring labor; this infant was HIV uninfected. The other infant was born to a woman who was infected with HCV genotype1a and had an HCV viral load of &#x0003e;850 000 copies/mL and an HIV viral load of20 342.  The mother of this infant didnot receive any antiretroviral prophylaxis; this infant was HIV infected.</p><p>The HIV vertical transmission rate amonginfants born to the 1429 HIV-infected women was 12.9% (<xref ref-type="table" rid="tab3">Table 3</xref>). There was a 9.4% (5/53) HIV transmission rate amongHCV-infected mothers and a 13.0% (170/1306) HIV transmission rate among HCV-uninfectedmothers (<italic>P</italic> = .445).  The odds of aninfant being HIV infected did not differ significantly by the mother's HCVstatus neither in unadjustedanalyses (odds ratio 0.70; 95% CI 0.27&#x02013;1.77), nor in analyses adjusted for perinatalstudy (adjusted odds ratio 0.82; 95% CI 0.32&#x02013;2.12).</p></sec><sec sec-type="section" id="sec4"><title>4. CONCLUSIONS</title><p>HCV infection in pregnancy isemerging as an increasingly important issue. Due to improved HCV blood screening, mother-to-child transmission of HCVhas now replaced transfusion-associated transmission as the predominant mode ofspread in children [<xref ref-type="bibr" rid="B1">1</xref>]. In this retrospectiveanalysis of more than 1700 pregnant women in Thailand, most of whom were HIV infected,we found relatively low hepatitis C seroprevalence rates.  Among the HIV-infected pregnant women, HCVseroprevalence was 3.8% and active HCV infection was 3.0%.  Among HIV-uninfected pregnant women, HCVseroprevalence was 0.3%.  The low rate ofinjection drug use in the population (1.5%) likely accounts for this relativelylow HCV seroprevalence, which is only slightly higher than many generalpopulations of pregnant women who are HIV uninfected. (1)  In a study conducted in Thailand  from1993-1994 among aconvenience sample of 120 HIV-infected women, 6.7% were anti-HCV positive by EIA[<xref ref-type="bibr" rid="B12">12</xref>].  In another study in Thailand  in1991, 2.7% of 883 women admitted to the hospital with gynecologic abnormalitieshad HCV antibodies [<xref ref-type="bibr" rid="B13">13</xref>].   Among Thaiwomen reporting injection drug use, higher HCV prevalence rates have beenreported, with 15% of 200 female injection drug users HCV infected in a recentstudy [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The risk factors for HCV infection identified, which included more education,intravenous drug use, having a partner with a history of injection drug use,ever having been a commercial sex worker, and having received a bloodtransfusion, were similar to risk factors associated with HCV in prior studies[<xref ref-type="bibr" rid="B15">15</xref>].  Although the number ofHIV-uninfected women was small in this study, we did not find HIV infection tobe a significant risk factor for HCV infection. As expected, a history ofinjection drug use was the strongest predictor of HCV infection (adjusted OR126; 95% CI 48.6&#x02013;326), similar to other studies among blood donors which have alsoidentified injection drug use as a strong risk factor for HCV infection [<xref ref-type="bibr" rid="B15">15</xref>].   There are six major HCV genotypes, which arenumbered 1&#x02013;6 and subtyped a, b, andc.  Type 1b is the most common genotypeworldwide.  Types 1a and 3a, which werethe predominant genotypes in the present study, are largely associated withinjection drug use [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>].</p><p>In the United States,routine HCV screening is recommended for persons with certain high-riskcharacteristics (e.g., history of injection drug use or blood transfusion) andfor children born to HCV-infected women [<xref ref-type="bibr" rid="B18">18</xref>]. However, routine screening is not recommended for pregnant women withoutother risk factors [<xref ref-type="bibr" rid="B19">19</xref>].  U.S.  guidelinesalso recommend that HIV-infected persons be routinely screened for HCV [<xref ref-type="bibr" rid="B20">20</xref>].  In Thailand, although current nationalguidelines do not address routine HCV screening or hepatitis testing forHIV-infected patients, most physicians provide hepatitis testing forHIV-infected adults with symptoms or risk factors, and pediatric providers intertiary care centers often test HIV-infected children who are at risk.  Pregnant women in antenatal clinics are alsoroutinely screened for  hepatitis B, but not HCV.  HCV treatment is available in Thailand  at cost to patientsor to patients with private health insurance.</p><p>The HCV perinataltransmission rate among infants born to HIV/HCV coinfected women in this study was4.2%.  However, due to the small numberof HCV-infected women in our sample, the confidence interval was wide.  The estimated frequency of HCV transmissionin this current study is similar to those of two recent multicenter studies conducted amongmostly HIV-uninfected women in the United States [<xref ref-type="bibr" rid="B21">21</xref>] and Europe [<xref ref-type="bibr" rid="B22">22</xref>] which reportedtransmission rates of 3.6% and 6.2%, respectively. Since HIV-infected women inthis cohort had relatively high CD4 counts at delivery, it is not clear howgeneralizable these findings are to other cohorts of HIV-infected pregnantwomen.  Although the published literaturehas shown a correlation of maternal HCV viral load and the risk of HCV verticaltransmission [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B23">23</xref>], there were too few HCV mother-to-child transmission inour study to draw conclusions.  However, bothHCV-infected infants born to HIV-infected women had high HCV viral loads.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors wish to thank the TUC laboratory staff for theiroutstanding work processing and testing all the specimens, and Daniel Newmanfor his extensive assistance with data management for the study. This studyreceived funding from the Opportunistic Infections Working Group at the Centersfor Disease Control and Prevention. The findings and conclusions in thisarticle are those of the authors and do not necessarily represent the officialposition of the Centers for Disease Control and Prevention.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>EA</given-names></name><name><surname>Yeung</surname><given-names>L</given-names></name></person-group><article-title>Maternal-infant transmission of hepatitis C virus infection</article-title><source><italic>Hepatology</italic></source><year>2002</year><volume>36</volume><issue>5B</issue><fpage>S106</fpage><lpage>S113</lpage><pub-id pub-id-type="pmid">12407583</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>GL</given-names></name><name><surname>Wasley</surname><given-names>A</given-names></name><name><surname>Simard</surname><given-names>EP</given-names></name><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>Kuhnert</surname><given-names>WL</given-names></name><name><surname>Alter</surname><given-names>MJ</given-names></name></person-group><article-title>The prevalence of hepatitis C virus infection in the United States, 1999 through 2002</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2006</year><volume>144</volume><issue>10</issue><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">16702586</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papaevangclou</surname><given-names>V</given-names></name><name><surname>Pollack</surname><given-names>H</given-names></name><name><surname>Rochford</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>1998</year><volume>178</volume><issue>4</issue><fpage>1047</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">9806033</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Villano</surname><given-names>SA</given-names></name><name><surname>Riester</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>1998</year><volume>177</volume><issue>6</issue><fpage>1480</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">9607823</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conte</surname><given-names>D</given-names></name><name><surname>Fraquelli</surname><given-names>M</given-names></name><name><surname>Prati</surname><given-names>D</given-names></name><name><surname>Colucci</surname><given-names>A</given-names></name><name><surname>Minola</surname><given-names>E</given-names></name></person-group><article-title>Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women</article-title><source><italic>Hepatology</italic></source><year>2000</year><volume>31</volume><issue>3</issue><fpage>751</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">10706568</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>SL</given-names></name><name><surname>Newell</surname><given-names>M-L</given-names></name><name><surname>Peckham</surname><given-names>CS</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Hall</surname><given-names>AJ</given-names></name></person-group><article-title>A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection</article-title><source><italic>International Journal of Epidemiology</italic></source><year>1998</year><volume>27</volume><issue>1</issue><fpage>108</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">9563703</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>LTF</given-names></name><name><surname>King</surname><given-names>SM</given-names></name><name><surname>Roberts</surname><given-names>EA</given-names></name></person-group><article-title>Mother-to-infant transmission of hepatitis C virus</article-title><source><italic>Hepatology</italic></source><year>2001</year><volume>34</volume><issue>2</issue><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">11481604</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaffer</surname><given-names>N</given-names></name><name><surname>Chuachoowong</surname><given-names>R</given-names></name><name><surname>Mock</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial</article-title><source><italic>The Lancet</italic></source><year>1999</year><volume>353</volume><issue>9155</issue><fpage>773</fpage><lpage>780</lpage></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaffer</surname><given-names>N</given-names></name><name><surname>Roongpisuthipong</surname><given-names>A</given-names></name><name><surname>Siriwasin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>1999</year><volume>179</volume><issue>3</issue><fpage>590</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">9952365</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teeraratkul</surname><given-names>A</given-names></name><name><surname>Simonds</surname><given-names>RJ</given-names></name><name><surname>Asavapiriyanont</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluating programs to prevent mother-to-child HIV transmission in two large Bangkok hospitals, 1999&#x02013;2001</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2005</year><volume>38</volume><issue>2</issue><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">15671807</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DL</given-names></name></person-group><article-title>Mother-infant hepatitis C transmission: second generation research</article-title><source><italic>Hepatology</italic></source><year>1999</year><volume>29</volume><issue>3</issue><fpage>992</fpage><lpage>993</lpage><pub-id pub-id-type="pmid">10051510</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suwanagool</surname><given-names>S</given-names></name><name><surname>Tieangrim</surname><given-names>S</given-names></name><name><surname>Ratanasuwan</surname><given-names>W</given-names></name><name><surname>Mekanantagosol</surname><given-names>S</given-names></name><name><surname>Luengrojanakul</surname><given-names>P</given-names></name><name><surname>Kunasol</surname><given-names>P</given-names></name></person-group><article-title>Seroprevalence of anti-HCV among HIV-infected persons and general population</article-title><source><italic>Journal of the Medical Association of Thailand</italic></source><year>1995</year><volume>78</volume><issue>11</issue><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">8576673</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roongpisuthipong</surname><given-names>A</given-names></name><name><surname>Suphanit</surname><given-names>I</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>The study of HCV antibody and serologic tests for syphilis in Thai patients with gynecologic disorders</article-title><source><italic>Asian Pacific Journal of Allergy and Immunology</italic></source><year>1993</year><volume>11</volume><issue>2</issue><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">7521643</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jittiwutikarn</surname><given-names>J</given-names></name><name><surname>Thongsawat</surname><given-names>S</given-names></name><name><surname>Suriyanon</surname><given-names>V</given-names></name><etal/></person-group><article-title>Hepatitis C infection among drug users in northern Thailand</article-title><source><italic>American Journal of Tropical Medicine and Hygiene</italic></source><year>2006</year><volume>74</volume><issue>6</issue><fpage>1111</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">16760529</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>EL</given-names></name><name><surname>Bryzman</surname><given-names>SM</given-names></name><name><surname>Glynn</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Risk factors for hepatitis C virus infection in united states blood donors</article-title><source><italic>Hepatology</italic></source><year>2000</year><volume>31</volume><issue>3</issue><fpage>756</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">10706569</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>P</given-names></name></person-group><article-title>Viral heterogeneity of the hepatitis C virus</article-title><source><italic>Journal of Hepatology, Supplement</italic></source><year>1999</year><volume>31</volume><issue>1</issue><fpage>54</fpage><lpage>60</lpage></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>P</given-names></name></person-group><article-title>Genetic diversity and evolution of hepatitis C virus&#x02014;15 years on</article-title><source><italic>Journal of General Virology</italic></source><year>2004</year><volume>85</volume><issue>11</issue><fpage>3173</fpage><lpage>3188</lpage><pub-id pub-id-type="pmid">15483230</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><collab>Centers for Disease Control and Prevention</collab><article-title>Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease</article-title><source><italic>MMWR Recommendations and Reports</italic></source><year>1998</year><volume>47</volume><issue>RR-19</issue><fpage>1</fpage><lpage>39</lpage></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><collab>American College of Obstetricians and Gynecologists</collab><article-title>ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992). American College of Obstetricians and Gynecologists</article-title><source><italic>International Journal of Gynecology &#x00026; Obstetrics</italic></source><year>1998</year><volume>63</volume><issue>2</issue><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">9856330</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>JE</given-names></name><name><surname>Masur</surname><given-names>H</given-names></name><name><surname>Holmes</surname><given-names>KK</given-names></name></person-group><article-title>Guidelines for preventing opportunistic infections among HIV-infected persons&#x02014;2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America</article-title><source><italic>MMWR Recommendations and Reports</italic></source><year>2002</year><volume>51</volume><issue>RR-8</issue><fpage>1</fpage><lpage>46</lpage></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mast</surname><given-names>EE</given-names></name><name><surname>Hwang</surname><given-names>L-Y</given-names></name><name><surname>Seto</surname><given-names>DSY</given-names></name><etal/></person-group><article-title>Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2005</year><volume>192</volume><issue>11</issue><fpage>1880</fpage><lpage>1889</lpage><pub-id pub-id-type="pmid">16267758</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tovo</surname><given-names>P-A</given-names></name><name><surname>Pembrey</surname><given-names>L</given-names></name><name><surname>Newell</surname><given-names>M-L</given-names></name></person-group><article-title>A significant sex&#x02014;but not elective cesarean section&#x02014;effect on mother-to-child transmission of hepatitis C virus infection</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2005</year><volume>192</volume><issue>11</issue><fpage>1872</fpage><lpage>1879</lpage><pub-id pub-id-type="pmid">16267757</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohto</surname><given-names>H</given-names></name><name><surname>Terazawa</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Transmission of hepatitis C virus from mothers to infants</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1994</year><volume>330</volume><issue>11</issue><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">8107740</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p> Demographic and clinical characteristics of1771 women enrolled in 3 vertical transmission HIV studiesin Bangkok, Thailand, 1992&#x02013;2004 (<italic>n</italic> (%)).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>Peri-1 (HIV &#x02212; )</italic>(<italic>n</italic> = 342)</th><th align="center" rowspan="1" colspan="1"><italic>Peri-1 (HIV+)</italic>(<italic>n</italic> = 293)</th><th align="center" rowspan="1" colspan="1"><italic>Peri-2</italic>(<italic>n</italic> = 391)</th><th align="center" rowspan="1" colspan="1"><italic>Peri-3</italic>(<italic>n</italic> = 745)</th><th align="center" rowspan="1" colspan="1"><italic>Total</italic>(<italic>n</italic> = 1771)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HCV status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Infected</td><td align="center" rowspan="1" colspan="1">1 (0.3)</td><td align="center" rowspan="1" colspan="1">5 (1.7)</td><td align="center" rowspan="1" colspan="1">16 (4.1)</td><td align="center" rowspan="1" colspan="1">33 (4.4)</td><td align="center" rowspan="1" colspan="1">55 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Uninfected</td><td align="center" rowspan="1" colspan="1">341 (99.7)</td><td align="center" rowspan="1" colspan="1">288 (98.3)</td><td align="center" rowspan="1" colspan="1">375 (95.9)</td><td align="center" rowspan="1" colspan="1">712 (95.6)</td><td align="center" rowspan="1" colspan="1">1716 (96.9)</td></tr><tr><td rowspan="1" colspan="1">Education</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Primary or less</td><td align="center" rowspan="1" colspan="1">227 (66.4)</td><td align="center" rowspan="1" colspan="1">197 (67.2)</td><td align="center" rowspan="1" colspan="1">225 (57.5)</td><td align="center" rowspan="1" colspan="1">418 (56.1)</td><td align="center" rowspan="1" colspan="1">1067 (60.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Greater than primary</td><td align="center" rowspan="1" colspan="1">115 (33.6)</td><td align="center" rowspan="1" colspan="1">96 (32.8)</td><td align="center" rowspan="1" colspan="1">166 (42.5)</td><td align="center" rowspan="1" colspan="1">327 (43.9)</td><td align="center" rowspan="1" colspan="1">704 (39.8)</td></tr><tr><td rowspan="1" colspan="1">Marital status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Married</td><td align="center" rowspan="1" colspan="1">179 (52.3)</td><td align="center" rowspan="1" colspan="1">174 (59.4)</td><td align="center" rowspan="1" colspan="1">185 (47.3)</td><td align="center" rowspan="1" colspan="1">248 (33.3)</td><td align="center" rowspan="1" colspan="1">786 (44.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Not married</td><td align="center" rowspan="1" colspan="1">163 (47.7)</td><td align="center" rowspan="1" colspan="1">119 (40.6)</td><td align="center" rowspan="1" colspan="1">206 (52.7)</td><td align="center" rowspan="1" colspan="1">497 (66.7)</td><td align="center" rowspan="1" colspan="1">985 (55.6)</td></tr><tr><td rowspan="1" colspan="1">Intravenous drug user (IDU)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3 (1.0)</td><td align="center" rowspan="1" colspan="1">5 (1.3)</td><td align="center" rowspan="1" colspan="1">19 (2.6)</td><td align="center" rowspan="1" colspan="1">27 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">342 (100)</td><td align="center" rowspan="1" colspan="1">290 (99.0)</td><td align="center" rowspan="1" colspan="1">386 (98.7)</td><td align="center" rowspan="1" colspan="1">726 (97.5)</td><td align="center" rowspan="1" colspan="1">1744 (98.5)</td></tr><tr><td rowspan="1" colspan="1">Any partners IDU*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">5 (1.5)</td><td align="center" rowspan="1" colspan="1">20 (7.1)</td><td align="center" rowspan="1" colspan="1">38 (10.6)</td><td align="center" rowspan="1" colspan="1">102 (15.9)</td><td align="center" rowspan="1" colspan="1">165 (10.2)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">335 (98.5)</td><td align="center" rowspan="1" colspan="1">260 (92.9)</td><td align="center" rowspan="1" colspan="1">321 (89.4)</td><td align="center" rowspan="1" colspan="1">539 (84.1)</td><td align="center" rowspan="1" colspan="1">1455 (89.8)</td></tr><tr><td rowspan="1" colspan="1">Ever a commercial sex worker*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">6 (1.8)</td><td align="center" rowspan="1" colspan="1">30 (10.2)</td><td align="center" rowspan="1" colspan="1">36 (9.3)</td><td align="center" rowspan="1" colspan="1">66 (8.9)</td><td align="center" rowspan="1" colspan="1">138 (7.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">336 (98.3)</td><td align="center" rowspan="1" colspan="1">263 (89.8)</td><td align="center" rowspan="1" colspan="1">353 (90.8)</td><td align="center" rowspan="1" colspan="1">679 (91.1)</td><td align="center" rowspan="1" colspan="1">1631 (92.2)</td></tr><tr><td rowspan="1" colspan="1">Received transfusion (1985&#x02013;89)*<sup>+</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">5 (1.5)</td><td align="center" rowspan="1" colspan="1">3 (1.0)</td><td align="center" rowspan="1" colspan="1">10 (2.6)</td><td align="center" rowspan="1" colspan="1">15 (2.0)</td><td align="center" rowspan="1" colspan="1">33 (1.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">334 (98.5)</td><td align="center" rowspan="1" colspan="1">290 (99.0)</td><td align="center" rowspan="1" colspan="1">380 (97.4)</td><td align="center" rowspan="1" colspan="1">730 (98.0)</td><td align="center" rowspan="1" colspan="1">1734 (98.1)</td></tr><tr><td rowspan="1" colspan="1">HIV subtype*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> E</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">273 (95.5)</td><td align="center" rowspan="1" colspan="1">318 (88.8)</td><td align="center" rowspan="1" colspan="1">559 (88.7)</td><td align="center" rowspan="1" colspan="1">1150 (90.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> B</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">10 (3.5)</td><td align="center" rowspan="1" colspan="1">22 (6.2)</td><td align="center" rowspan="1" colspan="1">45 (7.1)</td><td align="center" rowspan="1" colspan="1">77 (6.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> E/B</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">3 (1.1)</td><td align="center" rowspan="1" colspan="1">16 (4.5)</td><td align="center" rowspan="1" colspan="1">12 (1.9)</td><td align="center" rowspan="1" colspan="1">31 (2.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> BR/MN/C</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (0.6)</td><td align="center" rowspan="1" colspan="1">14 (2.2)</td><td align="center" rowspan="1" colspan="1">16 (1.3)</td></tr><tr><td rowspan="1" colspan="1">Delivery type*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Cesarean</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">33 (11.3)</td><td align="center" rowspan="1" colspan="1">56 (14.3)</td><td align="center" rowspan="1" colspan="1">188 (25.2)</td><td align="center" rowspan="1" colspan="1">277 (19.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Vaginal</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">260 (88.7)</td><td align="center" rowspan="1" colspan="1">335 (85.7)</td><td align="center" rowspan="1" colspan="1">557 (74.8)</td><td align="center" rowspan="1" colspan="1">1152 (80.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Maternal age, years [mean (range)]</td><td align="center" rowspan="1" colspan="1">24.5 (15&#x02013;40)</td><td align="center" rowspan="1" colspan="1">23.2 (14&#x02013;40)</td><td align="center" rowspan="1" colspan="1">24.9 (17&#x02013;39)</td><td align="center" rowspan="1" colspan="1">26.3 (15&#x02013;48)</td><td align="center" rowspan="1" colspan="1">25.1 (14&#x02013;48)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at 1st intercourse [mean (range)]</td><td align="center" rowspan="1" colspan="1">20.0 (13&#x02013;32)</td><td align="center" rowspan="1" colspan="1">19.3 (11&#x02013;35)</td><td align="center" rowspan="1" colspan="1">19.4 (12&#x02013;32)</td><td align="center" rowspan="1" colspan="1">18.6 (7&#x02013;44)</td><td align="center" rowspan="1" colspan="1">19.2 (7&#x02013;44)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gravidity [mean  (range)]</td><td align="center" rowspan="1" colspan="1">1.8 (1&#x02013;4)</td><td align="center" rowspan="1" colspan="1">1.6 (1&#x02013;4)</td><td align="center" rowspan="1" colspan="1">1.8 (1&#x02013;11)</td><td align="center" rowspan="1" colspan="1">2.1 (1&#x02013;7)</td><td align="center" rowspan="1" colspan="1">1.9 (1&#x02013;11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of sex partners in past year [mean (range)]</td><td align="center" rowspan="1" colspan="1">1.0 (1-2)</td><td align="center" rowspan="1" colspan="1">1.8 (1&#x02013;200)</td><td align="center" rowspan="1" colspan="1">1.1 (1&#x02013;6)</td><td align="center" rowspan="1" colspan="1">6.9 (1&#x02013;1428)</td><td align="center" rowspan="1" colspan="1">3.6 (1&#x02013;1428)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of hours in labor [mean (range)]</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">7.4 (0&#x02013;28)</td><td align="center" rowspan="1" colspan="1">10.6 (0&#x02013;57.9)</td><td align="center" rowspan="1" colspan="1">14.4 (0&#x02013;386)</td><td align="center" rowspan="1" colspan="1">12.0 (0&#x02013;386)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of membrane rupture, hours [mean (range)]</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">3.4 (0&#x02013;96)</td><td align="center" rowspan="1" colspan="1">4.0 (0&#x02013;39.5)</td><td align="center" rowspan="1" colspan="1">3.0 (0&#x02013;148)</td><td align="center" rowspan="1" colspan="1">3.4 (0&#x02013;148)</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV viral load at delivery, log<sub>10</sub>copies/mL [mean (range)]</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">4.4 (2.3&#x02013;6.2)</td><td align="center" rowspan="1" colspan="1">4.2 (2.3&#x02013;5.9)</td><td align="center" rowspan="1" colspan="1">3.8 (2.3&#x02013;6.0)</td><td align="center" rowspan="1" colspan="1">4.0 (2.3&#x02013;6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count at delivery, cells/mm<sup>3</sup> [mean (range)]</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">471 (140&#x02013;1180)</td><td align="center" rowspan="1" colspan="1">407 (11&#x02013;1112)</td><td align="center" rowspan="1" colspan="1">421 (8&#x02013;1608)</td><td align="center" rowspan="1" colspan="1">428 (8&#x02013;1608)</td></tr></tbody></table><table-wrap-foot><fn><p>*Sample size is decreased due to missing data.</p><p>						<sup>+</sup>Thailand began screening blood forHIV in 1989.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Odds ofbeing HCV-infected among 1771 pregnant women enrolled in 3 vertical transmission  HIV studies in Bangkok, Thailand, 1992&#x02013;2004.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1"><italic>HCV-infection</italic></th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Adjusted*</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Education</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Primary or less</td><td align="center" rowspan="1" colspan="1">1067</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">(24)</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Greater than primary</td><td align="center" rowspan="1" colspan="1">704</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">(31)</td><td align="center" rowspan="1" colspan="1">2.00 (1.16&#x02013;3.44)</td><td align="center" rowspan="1" colspan="1">1.81 (1.05&#x02013;3.12)</td></tr><tr><td rowspan="1" colspan="1">Marital status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Married</td><td align="center" rowspan="1" colspan="1">786</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">(18)</td><td align="center" rowspan="1" colspan="1">0.60 (0.34&#x02013;1.06)</td><td align="center" rowspan="1" colspan="1">0.72 (0.40&#x02013;1.29)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Not married</td><td align="center" rowspan="1" colspan="1">985</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">(37)</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">Intravenous drug user (IDU)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">74.1</td><td align="center" rowspan="1" colspan="1">(20)</td><td align="center" rowspan="1" colspan="1">140 (55.4&#x02013;351)</td><td align="center" rowspan="1" colspan="1">126 (48.6&#x02013;326)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">1744</td><td align="center" rowspan="1" colspan="1">2.0</td><td align="center" rowspan="1" colspan="1">(35)</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">Any partners IDU<sup>+</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">165</td><td align="center" rowspan="1" colspan="1">14.6</td><td align="center" rowspan="1" colspan="1">(24)</td><td align="center" rowspan="1" colspan="1">9.74 (5.42&#x02013;17.5)</td><td align="center" rowspan="1" colspan="1">7.92 (4.34&#x02013;14.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">1455</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">(25)</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">Ever a commercial sex worker<sup>+</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">138</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">(9)</td><td align="center" rowspan="1" colspan="1">2.40 (1.15&#x02013;5.02)</td><td align="center" rowspan="1" colspan="1">2.17 (1.03&#x02013;4.54)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">1631</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">(46)</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">Received transfusion (1985&#x02013;89)<sup>+</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Yes</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">12.1</td><td align="center" rowspan="1" colspan="1">(4)</td><td align="center" rowspan="1" colspan="1">4.65 (1.57&#x02013;13.7)</td><td align="center" rowspan="1" colspan="1">4.22 (1.41&#x02013;12.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> No</td><td align="center" rowspan="1" colspan="1">1734</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">(50)</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Maternal age, years</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">0.98 (0.93&#x02013;1.04)</td><td align="center" rowspan="1" colspan="1">0.96 (0.90&#x02013;1.02)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gravidity</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1.17 (0.93&#x02013;1.47)</td><td align="center" rowspan="1" colspan="1">1.09 (0.86&#x02013;1.38)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of sex partners in past year</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1.00 (0.996&#x02013;1.005)</td><td align="center" rowspan="1" colspan="1">1.00 (0.996&#x02013;1.005)</td></tr></tbody></table><table-wrap-foot><fn><p>*Adjusted for three perinatal studies.</p><p>						<sup>+</sup>Sample size is decreased due to missing data.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>HIV/HCV status and clinical characteristicsof infants born to 1429 HIV-infected women enrolled in 3 vertical transmission of HIVstudies in Bangkok, Thailand, 1992&#x02013;2004 (<italic>n</italic> (%)).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>Peri-1</italic>(<italic>n</italic> = 293)</th><th align="center" rowspan="1" colspan="1"><italic>Peri-2</italic>(<italic>n</italic> = 391)</th><th align="center" rowspan="1" colspan="1"><italic>Peri-3</italic>(<italic>n</italic> = 745)</th><th align="center" rowspan="1" colspan="1"><italic>Total</italic></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HIV status of infant*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Infected</td><td align="center" rowspan="1" colspan="1">68 (24.4)</td><td align="center" rowspan="1" colspan="1">55 (14.4)</td><td align="center" rowspan="1" colspan="1">52 (7.5)</td><td align="center" rowspan="1" colspan="1">175 (12.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Uninfected</td><td align="center" rowspan="1" colspan="1">211 (75.6)</td><td align="center" rowspan="1" colspan="1">327 (85.6)</td><td align="center" rowspan="1" colspan="1">646 (92.6)</td><td align="center" rowspan="1" colspan="1">1184 (87.1)</td></tr><tr><td rowspan="1" colspan="1">HCV status of infant</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Infected</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (0.5)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (0.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Uninfected</td><td align="center" rowspan="1" colspan="1">293 (100)</td><td align="center" rowspan="1" colspan="1">389 (99.5)</td><td align="center" rowspan="1" colspan="1">745 (100)</td><td align="center" rowspan="1" colspan="1">1427 (99.9)</td></tr><tr><td rowspan="1" colspan="1">Infant gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Male</td><td align="center" rowspan="1" colspan="1">136 (46.4)</td><td align="center" rowspan="1" colspan="1">207 (52.9)</td><td align="center" rowspan="1" colspan="1">365 (49.0)</td><td align="center" rowspan="1" colspan="1">708 (49.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> Female</td><td align="center" rowspan="1" colspan="1">157 (53.6)</td><td align="center" rowspan="1" colspan="1">184 (47.1)</td><td align="center" rowspan="1" colspan="1">380 (51.0)</td><td align="center" rowspan="1" colspan="1">721 (50.5)</td></tr><tr><td rowspan="1" colspan="1">Birthweight</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x0003c; 2500 g</td><td align="center" rowspan="1" colspan="1">31 (10.6)</td><td align="center" rowspan="1" colspan="1">31 (7.9)</td><td align="center" rowspan="1" colspan="1">81 (10.9)</td><td align="center" rowspan="1" colspan="1">143 (10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x02265; 2500 g</td><td align="center" rowspan="1" colspan="1">262 (89.4)</td><td align="center" rowspan="1" colspan="1">360 (92.1)</td><td align="center" rowspan="1" colspan="1">664 (89.1)</td><td align="center" rowspan="1" colspan="1">1286 (90.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gestational age [mean (range)]</td><td align="center" rowspan="1" colspan="1">39.4 (28&#x02013;44)</td><td align="center" rowspan="1" colspan="1">39.7 (35&#x02013;45)</td><td align="center" rowspan="1" colspan="1">38.7 (31&#x02013;44)</td><td align="center" rowspan="1" colspan="1">39.1 (28&#x02013;45)</td></tr></tbody></table><table-wrap-foot><fn><p>*Sample size is decreased due to missing data.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>